Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (NASDAQ: OCGN) will host a live webcast and conference call at 8:00 a.m. EDT on Tuesday, March 24, 2026 to discuss full Phase 2 ArMaDa clinical trial data for OCU410, a modifier gene therapy for geographic atrophy (late-stage dry AMD).
Key opinion leaders and Ocugen executives will present; a replay and archived webcast will be available on the company investor site. Dial-in and webcast details provided for attendees.
Ocugen (NASDAQ: OCGN) reported Q4 and full‑year 2025 results and a business update focused on three modifier gene therapy programs targeting BLAs over the next three years.
Key developments: completed enrollment (140 patients) in the Phase 3 OCU400 liMeliGhT trial with topline data expected Q1 2027 and a planned rolling BLA in Q3 2026; positive 12‑month OCU410 Phase 2 data (46% lesion growth reduction; p=0.015; N=23); exclusive Korean license for OCU400; $18.9M cash at year‑end and $22.5M financing in Jan 2026 extending runway into Q4 2026.
Ocugen (NASDAQ: OCGN) completed enrollment for the Phase 3 liMeliGhT trial of OCU400 in broad retinitis pigmentosa, randomizing 140 patients 2:1 into treated and untreated control arms. Topline Phase 3 data are expected in 1Q 2027, supporting a planned rolling BLA and potential approval in 2027.
Three‑year Phase 1/2 data show durable safety and tolerability, ~2‑line LLVA gain and 88% (7/8) evaluable treated subjects with improvement or preservation versus untreated eyes.
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to discuss fourth quarter and full year 2025 financial results and provide a business update.
A pre-market earnings announcement will be issued the same day. Dial-in numbers, conference ID, and a webcast link will be available on the company investor site; a replay and archived webcast will follow.
Ocugen (NASDAQ: OCGN) appointed Rita Johnson-Greene as Chief Financial Officer effective February 9, 2026. The company said she joins as Ocugen advances its gene‑therapy programs, including the planned submission of the first of three Biologics License Applications (BLAs) this year. Ms. Johnson‑Greene brings 20+ years in healthcare finance, operations and commercial roles at ARM, Genetix Biotherapeutics, Spark Therapeutics and AstraZeneca, and holds an MBA from Wharton and an engineering degree from Drexel University.
Ocugen (Nasdaq: OCGN) closed an underwritten registered direct offering of 15,000,000 shares of common stock at $1.50 per share, producing net proceeds of $20.85 million after commissions and expenses.
The financing was led by RTW Investments with participation from new and existing investors, and Oppenheimer & Co. acted as sole book-running manager. Ocugen said it intends to use proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses, and expects the funds to extend its cash runway into the fourth quarter of 2026. The offering was made pursuant to a shelf registration on Form S-3 (File No. 333-278774).
Ocugen (Nasdaq: OCGN) priced an underwritten offering of 15,000,000 shares of common stock at $1.50 per share for gross proceeds of $22.5 million, before commissions and offering expenses.
The offering is expected to close on or about January 22, 2026, subject to customary closing conditions. RTW Investments is leading the financing with participation from new and existing investors, and Oppenheimer & Co. is sole book-running manager. Ocugen said net proceeds will be used for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The offering is being made under a shelf registration on Form S-3 (File No. 333-278774); a prospectus supplement will be filed with the SEC.
Ocugen (NASDAQ: OCGN) reported positive preliminary 12-month data from the Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) for geographic atrophy (GA) secondary to dry AMD.
Key 12-month results: 46% lesion growth reduction (medium+high dose vs control; p=0.015; N=23), 54% reduction for medium dose (p=0.02; N=10), a 50% responder rate (>50% lesion reduction vs control), and subgroup (N=14) showing 57% greater reduction. Phase 1 evaluable eyes (N=7) showed 60% slower EZ loss versus fellow eyes. No OCU410-related serious adverse events reported across Phase 1 and Phase 2 (60 patients). Company aims to start Phase 3 in 2026 and pursue a BLA in 2028.
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast on Thursday, January 15, 2026 at 8:30 a.m. ET to discuss data from the first half of patients reaching one year after treatment in the OCU410 Phase 2 ArMaDa clinical trial. The event will feature KOLs and Ocugen executive leadership, including Dr. Arshad M. Khanani, Dr. Jay Chhablani, and Dr. Lejla Vajzovic.
Dial-in numbers: (800) 715-9871 (U.S.) and (646) 307-1963 (international); Conference ID: 7783588. A webcast and replay will be available on the company’s investor site events section.
Ocugen (NASDAQ: OCGN) published peer‑reviewed Phase 1 GARDian1 results for OCU410ST, a modifier gene therapy for Stargardt disease, reporting 12‑month safety, tolerability, and exploratory efficacy data.
Key findings in small Phase 1 cohort: 54% reduction in atrophic lesion growth in treated eyes versus fellow eyes, lesion expansion ~50% slower, treated eyes gained an average of +6 letters BCVA versus −1.5 letters in untreated eyes, 100% of treated eyes stabilized or improved, and no drug‑related serious adverse events. Phase 2/3 GARDian3 enrollment is expected to complete in Q1 2026 with a potential BLA filing in H1 2027.